MedTrace Logo

Xenon Inhalation for Treatment of Panic Disorder

NCT04432155 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-03-03

No results posted yet for this study

Summary

This study is a double-blind, randomized, placebo-controlled, clinical trial in parallel groups in patients with panic disorder.

Conditions

  • Panic Disorder

Interventions

DRUG

Xenon

30% xenon, 30% oxygen, and 40% nitrogen

DRUG

Placebo

30% oxygen, and 70% nitrogen

Sponsors & Collaborators

  • Nobilis Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2021-11-30
Completion
2021-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04432155 on ClinicalTrials.gov